The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 780K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
12
Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues.EBI
Ajinomoto
5
Interaction Analysis of FABP4 Inhibitors by X-ray Crystallography and Fragment Molecular Orbital Analysis.EBI
Ajinomoto
5
Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II.EBI
Ajinomoto
12
Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists.EBI
Ajinomoto
15
Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.EBI
Ajinomoto
39
Design, synthesis and evaluation of unnatural peptides as T1R2/T1R3 PAMs.EBI
Ajinomoto
25
Unnatural Tripeptides as Potent Positive Allosteric Modulators of T1R2/T1R3.EBI
Ajinomoto
16
The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels.EBI
Ajinomoto
27
Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.EBI
Ajinomoto
27
Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships.EBI
Ajinomoto
33
Heterocyclic carboxylic acid ester derivativeBDB
Ajinomoto
74
Pharmaceutical composition for treating diabetesBDB
Ajinomoto
33
Alkylamine derivativeBDB
Ajinomoto
94
Heteroarylcarboxylic acid ester derivativeBDB
Ajinomoto
81
Heteroarylcarboxylic acid ester derivativeBDB
Ajinomoto
129
Heteroarylcarboxylic acid ester derivativeBDB
Ajinomoto